Comparative Pharmacology
Head-to-head clinical analysis: AGGRASTAT versus EFFIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRASTAT versus EFFIENT.
AGGRASTAT vs EFFIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirofiban is a reversible antagonist of glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by blocking fibrinogen binding.
Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor on platelets, reducing ADP-mediated platelet aggregation.
A loading dose of 25 mcg/kg administered intravenously over 3 minutes, followed by a maintenance infusion of 0.15 mcg/kg/min for up to 18 hours. For patients with severe renal impairment (GFR <30 mL/min), the maintenance infusion rate is reduced to 0.075 mcg/kg/min.
Loading dose: 60 mg orally once. Maintenance: 10 mg orally once daily. In patients weighing <60 kg, maintenance dose is 5 mg orally once daily.
None Documented
None Documented
Terminal half-life: ~2 hours; clinical context: requires continuous IV infusion for sustained antiplatelet effect
The terminal elimination half-life of the active metabolite is about 7.6 hours (range 2-15 hours). Clinically, this supports once-daily dosing.
Renal: 65% unchanged drug; biliary/fecal: minimal (<5%)
Approximately 68% of the dose is excreted in urine as inactive metabolites, and about 27% in feces.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent